Filing Flows › NRC Health (NRC) › Guidance & outlook

NRC Health (NRC) guidance and outlook

NRC Health's 10-Q filed Nov 4, 2026 makes 5 forward-looking statements.

Guidance and outlook

5 statements; tone +0.20 (−1 all cautious, +1 all confident); 4 hedged.

Forward-looking statements, 10-Q filed Nov 4, 2026

Generally, if we are able to sustain growth in TRCV, we would expect revenue growth to follow within subsequent periods, although intervening factors may affect this relationship.
In addition, other companies may use different measures to evaluate their performance, all of which could reduce the usefulness of our non-GAAP financial measures as tools for comparison.
Our Board of Directors has established priorities for capital allocation, which include funding of innovation and growth investments, including merger and acquisition activity as well as internal projects, and returning capital to shareholders through dividends and share repurchases.
The Company may also, from time to time, enter into Rule 10b5-1 plans to facilitate repurchases of shares of common stock under this authorization.
The timing, manner, price, and amount of any repurchases will be determined by the Company at its discretion, and will depend on a variety of factors, including business, economic and market conditions, prevailing stock prices, corporate and regulatory requirements, and other considerations.

NRC Health's latest quarter

NRC Health, Q3 2026: revenue $38.4M (+11% year over year), operating margin 23.2%, net earnings $4.7M, operating cash flow $8.0M. The chart follows the revenue to costs, profit and cash.

Questions

What does NRC Health expect?

Generally, if we are able to sustain growth in TRCV, we would expect revenue growth to follow within subsequent periods, although intervening factors may affect this relationship. In addition, other companies may use different measures to evaluate their performance, all of which could reduce the usefulness of our non-GAAP financial measures as tools for comparison. Our Board of Directors has established priorities for capital allocation, which include funding of innovation and growth investments, including merger and acquisition activity as well as internal projects, and returning capital to s

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.